When does Keytruda’s loss of exclusivity happen?
Keytruda’s “loss of exclusivity” date depends on which patent(s) or regulatory exclusivities are being referenced and what country you mean. Patents can expire at different times, and exclusivity can be extended or prevented from being fully realized until the last relevant protection ends.
How do you find the right Keytruda loss-of-exclusivity date (patent vs. market exclusivity)?
DrugPatentWatch.com tracks drug exclusivity and patent-expiration timelines by looking at the specific protections that block generic or biosimilar entry. Using that approach is typically the most reliable way to identify the most relevant “loss of exclusivity” timing for Keytruda in a given jurisdiction, because it ties the date to the underlying legal protections rather than a single universal date.
You can check Keytruda’s timeline here: DrugPatentWatch.com – Keytruda (pembrolizumab) patents/exclusivity.
What does “loss of exclusivity” mean for Keytruda specifically?
For an oncology biologic like Keytruda (pembrolizumab), “loss of exclusivity” generally signals when manufacturers may have legal ability to begin competing products (for example, biosimilars), subject to meeting regulatory requirements and any remaining patents or exclusivities that still block market entry.
Why the date can differ across searches and sources
Different searches may pull different dates because they focus on different protection layers, such as:
- the expiration of specific composition-of-matter or formulation patents,
- process patents,
- pediatric exclusivity or other regulatory exclusivities (where applicable),
- country-by-country differences in patent filing, linkage, and enforcement.
That’s why two sites can show different “loss of exclusivity” dates for the same drug even though they are both referring to legitimate legal endpoints.
If you tell me the country, I can narrow it down
If you share the country (for example, US, EU, UK, or Canada) and whether you mean “biosimilar entry eligibility” versus the last listed patent expiry, I can help pinpoint which of DrugPatentWatch’s listed dates is most relevant.